Cargando…

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults

Vadadustat is a hypoxia‐inducible factor prolyl‐hydroxylase inhibitor being developed for the treatment of anemia in patients with chronic kidney disease. Sequelae of chronic kidney disease include hyperphosphatemia and anemia, which are frequently treated with phosphate binders and iron supplements...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paulson, Susan K., Martinez, Jimena, Sawant, Rishikesh, Burke, Steven K., Chavan, Ajit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305443/ https://www.ncbi.nlm.nih.gov/pubmed/35172045 http://dx.doi.org/10.1002/cpdd.1033

Ejemplares similares

Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
por: Negri, Armando Luis, et al.
Publicado: (2015)

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
por: Koury, Mark J., et al.
Publicado: (2022)

Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Correction to: Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis
por: Sarnak, Mark J, et al.
Publicado: (2023)

Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011)

Effects of iron-based phosphate binders on mortality and cardiovascular events in patients receiving maintenance dialysis
por: Tanaka, Akihito, et al.
Publicado: (2023)

Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells
por: Zielniok, Katarzyna, et al.
Publicado: (2020)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
por: Xiong, Limei, et al.
Publicado: (2022)

Effectiveness and cost-efficiency of phosphate binders in hemodialysis
por: Fröschl, Barbara, et al.
Publicado: (2009)

Preparation of acid aluminum phosphate solutions for metakaolin phosphate geopolymer binder
por: Yankwa Djobo, Jean Noël, et al.
Publicado: (2021)

Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders
por: Johansson, Susanne, et al.
Publicado: (2016)

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2014)

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients
por: Farrand, Kimberly F, et al.
Publicado: (2014)

Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2023)

Tolerability and efficacy of the intestinal phosphate binder Lantharenol(® )in cats
por: Schmidt, Bernard H, et al.
Publicado: (2012)

The demise of calcium-based phosphate binders—is this appropriate for children?
por: Rees, Lesley, et al.
Publicado: (2014)

Do we need new phosphate binders in dialysis?
por: Cozzolino, Mario, et al.
Publicado: (2020)

Phosphate binders in dialysis: better satisfied than sorry
por: Cozzolino, Mario, et al.
Publicado: (2021)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Efficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren® in healthy cats fed a standard diet
por: King, Jonathan N, et al.
Publicado: (2014)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
por: Rodby, Roger A., et al.
Publicado: (2015)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders
por: Bajait, Chaitali S, et al.
Publicado: (2014)

Research on preparation of phosphate-modified animal glue binder for foundry use
por: Wang, Tian-Shu, et al.
Publicado: (2018)

The role of kidney transplantation and phosphate binder use in vitamin K status
por: Jansz, Thijs T., et al.
Publicado: (2018)

Interventional study to improve adherence to phosphate binder treatment in dialysis patients
por: Hjemås, Bodil Jahren, et al.
Publicado: (2019)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Treated Patients
por: Parfrey, Patrick S., et al.
Publicado: (2023)

Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study
por: Schumacher, Stefan P, et al.
Publicado: (2018)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Naïve Patients
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2023)

Genistein as a dietary supplement; formulation, analysis and pharmacokinetics study
por: Mamagkaki, Alexandra, et al.
Publicado: (2021)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study
por: Leung, Simon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0fsovk11c9ic60ecsfkfuj3o6l